Micro-RNAs and copy number changes: New levels of gene regulation in acute myeloid leukemia

Chemico-Biological Interactions

Volumn 184, Issue 1-2, 2010, Pages 21-25

  Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute myeloid leukemia; Copy number alterations; Micro RNAs; MiR 181a; NPM1 mutations

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GENE PRODUCT; INTERLEUKIN 1BETA; MESSENGER RNA; MICRORNA; NUCLEOPHOSMIN; PROTEIN BAALC; PROTEIN MN1; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL RENEWAL; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOGENETICS; DISEASE FREE SURVIVAL; DOWN REGULATION; EFFECTOR CELL; GENE ACTIVATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; INNATE IMMUNITY; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RNA DEGRADATION; RNA TRANSLATION; SIGNAL TRANSDUCTION;

ANIMALS; GENE DOSAGE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; MUTATION; NUCLEAR PROTEINS;

EID: 77950627267     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.10.002     Document Type: Article

References (30)

1. Mrózek K., Marcucci G., Paschka P., et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109:431-448.
2. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 2005, 352:254-266.
3. Schlenk R.F., Döhner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 2008, 358:1909-1918.
4. Whitman S.P., Ruppert A.S., Radmacher M.D., et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008, 111:1552-1559.
5. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
6. Gale R.E., Green C., Allen C., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111:2776-2784.
7. Marcucci G., Maharry K., Radmacher M.D., et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study. J. Clin. Oncol. 2008, 26:5078-5087.
8. Paschka P., Marcucci G., Ruppert A.S., et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 2008, 26:4595-4602.
9. Baldus C.D., Tanner S.M., Ruppert A.S., et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study. Blood 2003, 102:1613-1618.
10. Falini B., Bolli N., Liso A., et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 2009, 23:1731-1743.
11. H. Becker, G. Marcucci, K. Maharry, et al., Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo AML, J Clin Oncol (in press).
12. Döhner K., Schlenk R.F., Habdank M., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005, 106:3740-3746.
13. Schnittger S., Schoch C., Kern W., et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005, 106:3733-3739.
14. Thiede C., Koch S., Creutzig E., et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia. Blood 2006, 107:4011-4020.
15. Byrd J.C., Mrózek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
16. Arber D.A., Vardiman J.W., Brunning R.D., et al. Acute myeloid leukaemia with recurrent genetic abnormalities. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 110-123. IARC, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, A. et (Eds.).
17. Redon R., et al. Global variation in copy number in the human genome. Nature 2006, 444:444-454.
18. Mullighan C.G., Downing J.R. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia 2009, 23:1209.
19. Walter J.M., Payton J.E., Ries R.E., et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12950-12955.
20. Radmacher M.D., Marcucci G., Ruppert A.S., et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 2006, 108:1677-1683.
21. Marcucci G., Radmacher R.D., Maharry K., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 2008, 358:1919-1928.
22. Schwind S., Marcucci G., Maharry K., Radmacher M.D., et al. for the CALGB: microRNA 181a expression as a prognosticator in cytogenetically normal acute myeloid leukemia. J. Clin. Oncol. 2009, 27:15s. (abstr 7001).
23. Saito Y., Jones R.A. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006, 5:2220-2222.
24. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
25. Li Z., Lu J., Sun M., et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15535-15540.
26. Fanini F., Vannini I., Faabbri M. MicroRNAs: tiny players with a big role in the pathogenesis of leukemias and lymphomas. Hematol. Rev. 2009, 1:40-45.
27. Garzon R., Garofalo M., Martelli M.P., et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3945-3950.
28. Andersen M.T., Andersen M.K., Christiansen D.H., Pedersen-Bjergaard J. NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features. Leukemia 2008, 22:951-955.
29. Baer M.R., George S.L., Dodge R.K., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720. Blood 2002, 100:1224-1232.
30. Marcucci G., Moser B., Blum W., et al. A phase III randomized trial of intensive induction and consolidation chemotherapy±oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. J. Clin. Oncol. 2007, 25:360s. (abstr 7012).